Background: Pemphigus is a chronic potentially life-threatening autoimmune blistering
disease affecting the skin and/or mucous membranes. Rituximab is being increasingly used …

Rituximab is currently approved for patients affected by moderate-to-severe pemphigus
vulgaris, a severe autoimmune blistering skin disease that can be life-threatening. The …

Rituximab is a chimeric monoclonal antibody that selectively binds to the CD20 molecule on
B cells, resulting in their lysis. In autoimmune blistering diseases, the auto-antibody …

Pemphigus is a severe autoimmune blistering disease mediated by pathogenic anti-
desmoglein antibodies leading to an inter keratinocyte disjunction. Rituximab is a …

Pemphigus Vulgaris (PV) is a rare autoimmune blistering disease, which mainly causes
mucosal and/or cutaneous lesions. In June 2018, FDA approved Rituximab (RTX)—a B‐cell …

J Oral Pathol Med (2011) 40: 616–620 Pemphigus vulgaris (PV) is a life‐threatening
autoimmune blistering disease affecting the skin and mucosa and is associated with …

Mucous membrane pemphigoid (MMP) is a heterogeneous group of rare, chronic,
subepithelial autoimmune blistering diseases (AIBDs) with predominant involvement of …

This was a multicenter clinical trial of rituximab, a chimeric monoclonal IgG antibody directed
against CD20, for the treatment of refractory pemphigus vulgaris and pemphigus foliaceus …

Pemphigus is a chronic and potentially fatal group of autoimmune blistering diseases, which
mainly affects mucous membranes and/or the skin. The two major types of pemphigus …

Importance The main component of the first-line treatment of pemphigus vulgaris is high
doses of systemic corticosteroids, but adverse effects of these drugs are frequent and …